GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy

Giuseppe Gaipa, Manuela Tilenni, Stefania Straino, Ilaria Burba, Germana Zaccagnini, Daniela Belotti, Ettore Biagi, Marco Valentini, Paolo Perseghin, Matteo Parma, Cristiana Di Campli, Andrea Biondi, Maurizio C. Capogrossi, Giulio Pompilio, Maurizio Pesce

Research output: Contribution to journalArticle

Abstract

The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the preparation of bone marrow (BM) derived CD133 + cells for cardiovascular repair. Starting from available laboratory protocols to purify CD133 + cells from human cord blood, we implemented these procedures in a GMP facility and applied quality control conditions defining purity, microbiological safety and vitality of CD133 + cells. Validation of CD133 + cells isolation and release process were performed according to a two-step experimental program comprising release quality checking (step 1) as well as 'proofs of principle' of their phenotypic integrity and biological function (step 2). This testing program was accomplished using in vitro culture assays and in vivo testing in an immunosuppressed mouse model of hindlimb ischemia. These criteria and procedures were successfully applied to GMP production of CD133 + cells from the BM for an ongoing clinical trial of autologous stem cells administration into patients with ischemic cardiomyopathy. Our results show that GMP implementation of currently available protocols for CD133 + cells selection is feasible and reproducible, and enables the production of cells having a full biological potential according to the most recent quality requirements by European Regulatory Agencies.

Original languageEnglish
Pages (from-to)1619-1634
Number of pages16
JournalJournal of Cellular and Molecular Medicine
Volume14
Issue number6 B
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Cell Separation
Cell- and Tissue-Based Therapy
Hindlimb
Fetal Blood
Cardiomyopathies
Bone Marrow Cells
Quality Control
Stem Cells
Ischemia
Bone Marrow
Clinical Trials
Safety

Keywords

  • Angiogenesis
  • CD133
  • Cell therapy
  • GMP
  • Ischemia
  • Validation

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. / Gaipa, Giuseppe; Tilenni, Manuela; Straino, Stefania; Burba, Ilaria; Zaccagnini, Germana; Belotti, Daniela; Biagi, Ettore; Valentini, Marco; Perseghin, Paolo; Parma, Matteo; Campli, Cristiana Di; Biondi, Andrea; Capogrossi, Maurizio C.; Pompilio, Giulio; Pesce, Maurizio.

In: Journal of Cellular and Molecular Medicine, Vol. 14, No. 6 B, 06.2010, p. 1619-1634.

Research output: Contribution to journalArticle

Gaipa, G, Tilenni, M, Straino, S, Burba, I, Zaccagnini, G, Belotti, D, Biagi, E, Valentini, M, Perseghin, P, Parma, M, Campli, CD, Biondi, A, Capogrossi, MC, Pompilio, G & Pesce, M 2010, 'GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy', Journal of Cellular and Molecular Medicine, vol. 14, no. 6 B, pp. 1619-1634. https://doi.org/10.1111/j.1582-4934.2009.00854.x
Gaipa, Giuseppe ; Tilenni, Manuela ; Straino, Stefania ; Burba, Ilaria ; Zaccagnini, Germana ; Belotti, Daniela ; Biagi, Ettore ; Valentini, Marco ; Perseghin, Paolo ; Parma, Matteo ; Campli, Cristiana Di ; Biondi, Andrea ; Capogrossi, Maurizio C. ; Pompilio, Giulio ; Pesce, Maurizio. / GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. In: Journal of Cellular and Molecular Medicine. 2010 ; Vol. 14, No. 6 B. pp. 1619-1634.
@article{959ec5b7307c44d2a19772fa2e4c0845,
title = "GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy",
abstract = "The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the preparation of bone marrow (BM) derived CD133 + cells for cardiovascular repair. Starting from available laboratory protocols to purify CD133 + cells from human cord blood, we implemented these procedures in a GMP facility and applied quality control conditions defining purity, microbiological safety and vitality of CD133 + cells. Validation of CD133 + cells isolation and release process were performed according to a two-step experimental program comprising release quality checking (step 1) as well as 'proofs of principle' of their phenotypic integrity and biological function (step 2). This testing program was accomplished using in vitro culture assays and in vivo testing in an immunosuppressed mouse model of hindlimb ischemia. These criteria and procedures were successfully applied to GMP production of CD133 + cells from the BM for an ongoing clinical trial of autologous stem cells administration into patients with ischemic cardiomyopathy. Our results show that GMP implementation of currently available protocols for CD133 + cells selection is feasible and reproducible, and enables the production of cells having a full biological potential according to the most recent quality requirements by European Regulatory Agencies.",
keywords = "Angiogenesis, CD133, Cell therapy, GMP, Ischemia, Validation",
author = "Giuseppe Gaipa and Manuela Tilenni and Stefania Straino and Ilaria Burba and Germana Zaccagnini and Daniela Belotti and Ettore Biagi and Marco Valentini and Paolo Perseghin and Matteo Parma and Campli, {Cristiana Di} and Andrea Biondi and Capogrossi, {Maurizio C.} and Giulio Pompilio and Maurizio Pesce",
year = "2010",
month = "6",
doi = "10.1111/j.1582-4934.2009.00854.x",
language = "English",
volume = "14",
pages = "1619--1634",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "6 B",

}

TY - JOUR

T1 - GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy

AU - Gaipa, Giuseppe

AU - Tilenni, Manuela

AU - Straino, Stefania

AU - Burba, Ilaria

AU - Zaccagnini, Germana

AU - Belotti, Daniela

AU - Biagi, Ettore

AU - Valentini, Marco

AU - Perseghin, Paolo

AU - Parma, Matteo

AU - Campli, Cristiana Di

AU - Biondi, Andrea

AU - Capogrossi, Maurizio C.

AU - Pompilio, Giulio

AU - Pesce, Maurizio

PY - 2010/6

Y1 - 2010/6

N2 - The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the preparation of bone marrow (BM) derived CD133 + cells for cardiovascular repair. Starting from available laboratory protocols to purify CD133 + cells from human cord blood, we implemented these procedures in a GMP facility and applied quality control conditions defining purity, microbiological safety and vitality of CD133 + cells. Validation of CD133 + cells isolation and release process were performed according to a two-step experimental program comprising release quality checking (step 1) as well as 'proofs of principle' of their phenotypic integrity and biological function (step 2). This testing program was accomplished using in vitro culture assays and in vivo testing in an immunosuppressed mouse model of hindlimb ischemia. These criteria and procedures were successfully applied to GMP production of CD133 + cells from the BM for an ongoing clinical trial of autologous stem cells administration into patients with ischemic cardiomyopathy. Our results show that GMP implementation of currently available protocols for CD133 + cells selection is feasible and reproducible, and enables the production of cells having a full biological potential according to the most recent quality requirements by European Regulatory Agencies.

AB - The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the preparation of bone marrow (BM) derived CD133 + cells for cardiovascular repair. Starting from available laboratory protocols to purify CD133 + cells from human cord blood, we implemented these procedures in a GMP facility and applied quality control conditions defining purity, microbiological safety and vitality of CD133 + cells. Validation of CD133 + cells isolation and release process were performed according to a two-step experimental program comprising release quality checking (step 1) as well as 'proofs of principle' of their phenotypic integrity and biological function (step 2). This testing program was accomplished using in vitro culture assays and in vivo testing in an immunosuppressed mouse model of hindlimb ischemia. These criteria and procedures were successfully applied to GMP production of CD133 + cells from the BM for an ongoing clinical trial of autologous stem cells administration into patients with ischemic cardiomyopathy. Our results show that GMP implementation of currently available protocols for CD133 + cells selection is feasible and reproducible, and enables the production of cells having a full biological potential according to the most recent quality requirements by European Regulatory Agencies.

KW - Angiogenesis

KW - CD133

KW - Cell therapy

KW - GMP

KW - Ischemia

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=77955153717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955153717&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2009.00854.x

DO - 10.1111/j.1582-4934.2009.00854.x

M3 - Article

C2 - 19627397

AN - SCOPUS:77955153717

VL - 14

SP - 1619

EP - 1634

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 6 B

ER -